According to our recent payer coverage analysis for acute myeloid leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for acute myeloid leukemia treatments shows that under the pharmacy benefit, about 65% and 80% of the lives under commercial and Medicare formularies are covered with utilization management restrictions.
Trends: In June 2019, Daiichi Sankyo Company, Ltd. said that the FDA had issued a complete response letter (CRL) for its new drug application (NDA) for quizartinib for the treatment of adults with R/R FLT3-internal tandem duplications acute myeloid leukemia.